高级检索
当前位置: 首页 > 详情页

Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II and III adenocarcinoma of the esophagogastric junction

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [2]Department of General Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
出处:
ISSN:

关键词: Adenocarcinoma of the esophagogastric junction Preoperative therapy Chemoradiotherapy Chemotherapy

摘要:
Purpose: Preoperative therapy improves overall survival (OS) after surgery in patients with adenocarcinoma of the esophagogastric junction (AEG). We aimed to retrospectively analyze whether preoperative chemoradiotherapy (CRT) could improve the prognosis of patients with locally advanced Siewert II and III AEG comparing with preoperative chemotherapy alone (CT). Patients and methods: From March 2012 to December 2015, 170 patients with locally advanced (cT3-4NxM0) Siewert II and Ill AEG were treated with preoperative CRT or CT in Hebei Medical University Fourth Hospital, and 123 patients were included in this study to compare the effects of preoperative CRT with CT. Results: RO resection rate was 96.7% in CRT group and 82.5% in CT group (P = .016). The pathological complete response was 16.7% after CRT group and 3.2% after CT (P = .015). The median follow-up time was 20 months. The 1- and 3-year OS were 89.4%, 79.2% in CRT group and 88.2%, 58.0% in CT group (P = .016; HR = 0.40, 95% confidence interval 0.21-0.76). The 1- and 3-year PFS were 87.3%, 73.5% in CRT group and 72.8%, 42.8% in CT group (P = .014; HR = 0.46, 95% confidence interval 0.24-0.86). Multivariate analysis showed that clinical T stage, adjuvant chemotherapy cycles and histologic differentiation were shown to be the independent prognostic factors for OS, and postoperative pathologic N stage was shown to be the independent prognostic factor for PFS. Conclusion: For the patients with locally advanced AEG, the addition of radiotherapy to preoperative chemotherapy can improve survival with safety, but is not an independent prognostic factor for OS and PFS. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 3 区 医学
小类 | 2 区 外科 3 区 肿瘤学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 肿瘤学 2 区 外科
JCR分区:
出版当年[2018]版:
Q1 SURGERY Q2 ONCOLOGY
最新[2023]版:
Q1 SURGERY Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China
共同第一作者:
通讯作者:
通讯机构: [1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China [*1]Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, 050011, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号